No Data
No Data
No Data
No Data
No Data
We Think Zymeworks (NASDAQ:ZYME) Can Afford To Drive Business Growth
Yahoo FinanceApr 28 22:26
HER2+ Market to Accelerate Substantially by 2034, Predicts DelveInsight | Key Companies - Zymeworks, Jazz Pharmaceuticals, Ambrx, AnBogen Therapeutics, Enliven Therapeutics, Roche
New York, USA, April 17, 2024 (GLOBE NEWSWIRE) -- HER2+ Market to Accelerate Substantially by 2034, Predicts DelveInsight | Key Companies - Zymeworks, Jazz Pharmaceuticals, Ambrx, AnBogen Therapeutics, Enliven
GlobeNewswireApr 18 01:00
Maintaining Hold on Zymeworks: ZW191's Potential Amidst Competitive and Regulatory Hurdles
TipRanksApr 12 18:27
Zymeworks Announces Upcoming Financial Report
TipRanksApr 11 18:37
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve
GlobeNewswireApr 11 18:00
Zymeworks Unveils Promising Cancer Research
TipRanksApr 8 19:07
No Data
No Data